Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-targeted CAR-T in Advanced Solid Tumors
NCT06010862Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CEA CAR-T cells in gastric cancer (GC), colon cancer, pancreatic cancer (PC) and 4 more (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Adverse events after CEA CAR-T cells infusion at 28 days and Maximum tolerated dose of CEA CAR-T cells at 28 days. Started Sep 2023; status: recruiting.
02
Drugs
CEA CAR-T cells
03
Conditions
gastric cancer (GC)colon cancerpancreatic cancer (PC)esophageal cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06010862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010862.